Taken together, these findings demonstrate that KEAP1 is required for the anticancer activity of artesunate and support the further development of the combination of artesunate and NRF2 inhibitors to treat NSCLC, especially when patients have a mutation in the KEAP1/NRF2 pathway. Here, KEAP1 is linked to non-small cell lung carcinoma.